Thrombomodulin: A bifunctional modulator of inflammation and coagulation in sepsis

Critical Care Research and Practice

Volumn 2012, Issue , 2012, Pages

  Okamoto, Takayuki ^a   Tanigami, Hironobu ^b   Suzuki, Koji ^a,c   Shimaoka, Motomu ^a,b  

^a MIE UNIVERSITY   (Japan)

^b OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^c SUZUKA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84866253982     PISSN: 20901305     EISSN: 20901313     Source Type: Journal    
DOI: 10.1155/2012/614545     Document Type: Review

References (95)

1. Russell J. A., Management of sepsis. The New England Journal of Medicine 2006 355 16 1699 1713 2-s2.0-33750047495 10.1056/NEJMra043632 (Pubitemid 44583960)
2. Martin G. S., Mannino D. M., Eaton S., Moss M., The epidemiology of sepsis in the United States from 1979 through 2000. The New England Journal of Medicine 2003 348 16 1546 1554 2-s2.0-0037451929 10.1056/NEJMoa022139 (Pubitemid 36437931)
3. Rice T. W., Bernard G. R., Therapeutic intervention and targets for sepsis. Annual Review of Medicine 2005 56 225 248 2-s2.0-14544299688 10.1146/annurev.med.56.082103.104356 (Pubitemid 40299782)
4. Ait-Oufella H., Maury E., Lehoux S., Guidet B., Offenstadt G., The endothelium: physiological functions and role in microcirculatory failure during severe sepsis. Intensive Care Medicine 2010 36 8 1286 1298 2-s2.0-77956258291 10.1007/s00134-010-1893-6
5. Zeerleder S., Hack C. E., Wuillemin W. A., Disseminated intravascular coagulation in sepsis. Chest 2005 128 4 2864 2875 2-s2.0-27144451165 10.1378/chest.128.4.2864 (Pubitemid 41507648)
6. Bernard G. R., Vincent J. L., Laterre P. F., LaRosa S. P., Dhainaut J. F., Lopez-Rodriguez A., Steingrub J. S., Garber G. E., Helterbrand J. D., Ely E. W., Fisher C. J., Efficacy and safety of recombinant human activated protein C for severe sepsis. The New England Journal of Medicine 2001 344 10 699 709 2-s2.0-0035826096 10.1056/NEJM200103083441001 (Pubitemid 32204987)
7. Aikawa N., Shimazaki S., Yamamoto Y., Saito H., Maruyama I., Ohno R., Hirayama A., Aoki Y., Aoki N., Thrombomodulin alfa in the treatment of infectious patients complicated by disseminated intravascular coagulation: sub-analysis from the phase III trial. Shock 2011 35 4 349 354 2-s2.0-78149305222 10.1097/SHK.0b013e318204c019
8. Yamakawa K., Fujimi S., Mohri T., Treatment effects of recombinant human soluble thrombomodulin in patients with severe sepsis: a historical control study. Critical Care 2011 15 3 R123
9. Saito H., Maruyama I., Shimazaki S., Yamamoto Y., Aikawa N., Ohno R., Hirayama A., Matsuda T., Asakura H., Nakashima M., Aoki N., Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial. Journal of Thrombosis and Haemostasis 2007 5 1 31 41 2-s2.0-33845513582 10.1111/j.1538-7836.2006.02267.x (Pubitemid 44921064)
10. Moll S., Lindley C., Pescatore S., Morrison D., Tsuruta K., Mohri M., Serada M., Sata M., Shimizu H., Yamada K., White G. C., Phase I study of a novel recombinant human soluble thrombomodulin, ART-123. Journal of Thrombosis and Haemostasis 2004 2 10 1745 1751 2-s2.0-19944432294 10.1111/j.1538-7836.2004. 00927.x (Pubitemid 40192715)
11. Kearon C., Comp P., Douketis J., Royds R., Yamada K., Gent M., Dose-response study of recombinant human soluble thrombomodulin (ART-123) in the prevention of venous thromboembolism after total hip replacement. Journal of Thrombosis and Haemostasis 2005 3 5 962 968 2-s2.0-23844438376 10.1111/j.1538-7836.2005.01251.x (Pubitemid 41632827)
12. Levi M., van der Poll T., Inflammation and coagulation. Critical Care Medicine 2010 38 2 S26 S34 2-s2.0-74949117097 10.1097/CCM.0b013e3181c98d21
13. Esmon C. T., The interactions between inflammation and coagulation. British Journal of Haematology 2005 131 4 417 430 2-s2.0-33644801469 10.1111/j.1365-2141.2005.05753.x (Pubitemid 43899639)
14. Mackman N., nmackman@med.unc.edu The many faces of tissue factor. Journal of Thrombosis and Haemostasis 2009 7 supplement 1 136 139 10.1111/j.1538-7836. 2009.03368.x
15. Popovic M., Smiljanic K., Dobutovic B., Syrovets T., Simmet T., Isenovic E. R., Thrombin and vascular inflammation. Molecular and Cellular Biochemistry 2012 359 1-2 301 313 10.1007/s11010-011-1024-x
16. Coughlin S. R., Protease-activated receptors in hemostasis, thrombosis and vascular biology. Journal of Thrombosis and Haemostasis 2005 3 8 1800 1814 2-s2.0-28344436780 10.1111/j.1538-7836.2005.01377.x (Pubitemid 41716567)
17. Bizios R., Lai L., Fenton J. W., Malik A. B., Thrombin-induced chemotaxis and aggregation of neutrophils. Journal of Cellular Physiology 1986 128 3 485 490 2-s2.0-0022470963 (Pubitemid 16015533)
18. McEver R. P., Leukocyte-endothelial cell interactions. Current Opinion in Cell Biology 1992 4 5 840 849 2-s2.0-0026938894
19. Johnson K., Choi Y., DeGroot E., Samuels I., Creasey A., Aarden L., Potential mechanisms for a proinflammatory vascular cytokine response to coagulation activation. Journal of Immunology 1998 160 10 5130 5135 2-s2.0-0032525041 (Pubitemid 28215352)
20. Naldini A., Carney D. H., Bocci V., Klimpel K. D., Asuncion M., Soares L. E., Klimpel G. R., Thrombin enhances T cell proliferative responses and cytokine production. Cellular Immunology 1993 147 2 367 377 2-s2.0-0027511564 10.1006/cimm.1993.1076 (Pubitemid 23113934)
21. 1 Journal of Cellular Physiology 2002 191 3 290 297 (Pubitemid 34462479)
22. Conway E. M., Thrombomodulin and its role in inflammation. Seminars in Immunopathology 2012 34 1 107 125 10.1007/s00281-011-0282-8
23. Adams T. E., Huntington J. A., Thrombin-cofactor interactions: structural insights into regulatory mechanisms. Arteriosclerosis, Thrombosis, and Vascular Biology 2006 26 8 1738 1745 2-s2.0-33746859068 10.1161/01.ATV.0000228844.65168. d1 (Pubitemid 44305326)
24. Stearns-Kurosawa D. J., Kurosawa S., Mollica J. S., Ferrell G. L., Esmon C. T., The endothelial cell protein C receptor augments protein C activation by the thrombin-thrombomodulin complex. Proceedings of the National Academy of Sciences of the United States of America 1996 93 19 10212 10216 2-s2.0-0029790055 10.1073/pnas.93.19.10212 (Pubitemid 26314601)
25. Yuksel M., Okajima K., Uchiba M., Horiuchi S., Okabe H., Activated protein C inhibits lipopolysaccharide-induced tumor necrosis factor- α production by inhibiting activation of both nuclear factor- κ B and activator protein-1 in human monocytes. Thrombosis and Haemostasis 2002 88 2 267 273 2-s2.0-0036339949 (Pubitemid 34873708)
26. Murakami K., Okajima K., Uchiba M., Johno M., Nakagaki T., Okabe H., Takatsuki K., Activated protein C attenuates endotoxin-induced pulmonary vascular injury by inhibiting activated leukocytes in rats. Blood 1996 87 2 642 647 2-s2.0-0030034186 (Pubitemid 26030319)
27. Bajzar L., Morser J., Nesheim M., TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex. Journal of Biological Chemistry 1996 271 28 16603 16608 2-s2.0-0029895009 10.1074/jbc.271.28.16603 (Pubitemid 26239017)
28. Campbell W. D., Lazoura E., Okada N., Okada H., Inactivation of C3a and C5a octapeptides by carboxypeptidase R and carboxypeptidase N. Microbiology and Immunology 2002 46 2 131 134 2-s2.0-0036191244 (Pubitemid 34194973)
29. Weiler H., Isermann B. H., Thrombomodulin. Journal of Thrombosis and Haemostasis 2003 1 7 1515 1524 2-s2.0-0141498158
30. Suzuki K., Kusumoto H., Deyashiki Y., Nishioka J., Maruyama I., Zushi M., Kawahara S., Honda G., Yamamoto S., Horiguchi S., Structure and expression of human thrombomodulin, a thrombin receptor on endothelium acting as a cofactor for protein C activation. EMBO Journal 1987 6 7 1891 1897 2-s2.0-0023374585
31. Sadler J. E., Thrombomodulin structure and function. Thrombosis and Haemostasis 1997 78 1 392 395 2-s2.0-0030843884 (Pubitemid 27289273)
32. Conway E. M., Pollefeyt S., Collen D., Steiner-Mosonyi M., The amino terminal lectin-like domain of thrombomodulin is required for constitutive endocytosis. Blood 1997 89 2 652 661 2-s2.0-0031023957 (Pubitemid 27051702)
33. Conway E. M., Van de Wouwer M., Pollefeyt S., Jurk K., Van Aken H., De Vriese A., Weitz J. I., Weiler H., Hellings P. W., Schaeffer P., Herbert J. M., Collen D., Theilmeier G., The lectin-like domain of thrombomodulin confers protection from neutrophil-mediated tissue damage by suppressing adhesion molecule expression via nuclear factor κ B and mitogen-activated protein kinase pathways. Journal of Experimental Medicine 2002 196 5 565 577 2-s2.0-0036719075 10.1084/jem.20020077 (Pubitemid 35024436)
34. Hamada H., Ishii H., Sakyo K., Horie S., Nishiki K., Kazama M., The epidermal growth factor-like domain of recombinant human thrombomodulin exhibits mitogenic activity for Swiss 3T3 cells. Blood 1995 86 1 225 233 2-s2.0-0029050715
35. Tohda G., Oida K., Okada Y., Kosaka S., Okada E., Takahashi S., Ishii H., Miyamori I., Expression of thrombomodulin in atherosclerotic lesions and mitogenic activity of recombinant thrombomodulin in vascular smooth muscle cells. Arteriosclerosis, Thrombosis, and Vascular Biology 1998 18 12 1861 1869 2-s2.0-0031674015 (Pubitemid 28565747)
36. Esmon C. T., Esmon N. L., Harris K. W., Complex formation between thrombin and thrombomodulin inhibits both thrombin-catalyzed fibrin formation and factor V activation. Journal of Biological Chemistry 1982 257 14 7944 7947 2-s2.0-0020404408 (Pubitemid 13241217)
37. Esmon N. L., Carroll R. C., Esmon C. T., Thrombomodulin blocks the ability of thrombin to activate platelets. Journal of Biological Chemistry 1983 258 20 12238 12242 2-s2.0-0021053984 (Pubitemid 14230011)
38. Hofsteenge J., Taguchi H., Stone S. R., Effect of thrombomodulin on the kinetics of the interaction of thrombin with substrates and inhibitors. Biochemical Journal 1986 237 1 243 251 2-s2.0-0022529127 (Pubitemid 16063113)
39. Tsiang M., Lentz S. R., Sadler J. E., Functional domains of membrane-bound human thrombomodulin. EGF-like domains four to six and the serine/threonine-rich domain are required for cofactor activity. Journal of Biological Chemistry 1992 267 9 6164 6170 2-s2.0-0026775230
40. Wang W., Nagashima M., Schneider M., Morser J., Nesheim M., Elements of the primary structure of thrombomodulin required for efficient thrombin-activable fibrinolysis inhibitor activation. Journal of Biological Chemistry 2000 275 30 22942 22947 2-s2.0-0034725622 10.1074/jbc.M001760200 (Pubitemid 30646181)
41. Wu C., Kim P. Y., Manuel R., Seto M., Whitlow M., Nagashima M., Morser J., Gils A., Declerck P., Nesheim M. E., The roles of selected arginine and lysine residues of TAFI (Pro-CPU) in its activation to TAFIa by the thrombin-thrombomodulin complex. Journal of Biological Chemistry 2009 284 11 7059 7067 2-s2.0-65449180750 10.1074/jbc.M804745200
42. Koyama T., Parkinson J. F., Sie P., Bang N. U., Muller-Berghaus G., Preissner K. T., Different glycoforms of human thrombomodulin. Their glycosaminoglycan-dependent modulatory effects on thrombin inactivation by heparin cofactor II and antithrombin III. European Journal of Biochemistry 1991 198 3 563 570 2-s2.0-0025763975
43. Elisen M. G., Von Dem Borne P. A., Bouma B. N., Meijers J. C., Protein C inhibitor acts as a procoagulant by inhibiting the thrombomodulin-induced activation of protein C in human plasma. Blood 1998 91 5 1542 1547 2-s2.0-0032030653 (Pubitemid 28110317)
44. Mosnier L. O., Platelet factor 4 inhibits thrombomodulin-dependent activation of thrombin-activatable fibrinolysis inhibitor (TAFI) by thrombin. Journal of Biological Chemistry 2011 286 1 502 510 2-s2.0-78650934956 10.1074/jbc.M110.147959
45. De Cristofaro R., De Candia E., Landolfi R., Effect of high- and low-molecular-weight heparins on thrombin- thrombomodulin interaction and protein C activation. Circulation 1998 98 13 1297 1301 2-s2.0-0032578548 (Pubitemid 28443393)
46. Conway E. M., Nowakowski B., Steiner-Mosonyi M., Thrombomodulin lacking the cytoplasmic domain efficiently internalizes thrombin via nonclathrin-coated, pit-mediated endocytosis. Journal of Cellular Physiology 1994 158 2 285 298 2-s2.0-0028039927 (Pubitemid 24063556)
47. 2+ signals and nitric oxide synthesis through epidermal growth factor receptor kinase and calmodulin kinase II. Journal of Biological Chemistry 2005 280 43 35999 36006 10.1074/jbc.M506374200 (Pubitemid 41633869)
48. Healy A. M., Rayburn H. B., Rosenberg R. D., Weiler H., Absence of the blood-clotting regulator thrombomodulin causes embryonic lethality in mice before development of a functional cardiovascular system. Proceedings of the National Academy of Sciences of the United States of America 1995 92 3 850 854 2-s2.0-0028876697 10.1073/pnas.92.3.850
49. Isermann B., Hendrickson S. B., Hutley K., Wing M., Weiler H., Tissue-restricted expression of thrombomodulin in the placenta rescues thrombomodulin-deficient mice from early lethality and reveals a secondary developmental block. Development 2001 128 6 827 838 2-s2.0-0035070573 (Pubitemid 32288194)
50. Conway E. M., Pollefeyt S., Cornelissen J., DeBaere I., Steiner-Mosonyi M., Weitz J. I., Weiler-Guettler H., Carmeliet P., Collen D., Structure-function analyses of thrombomodulin by gene-targeting in mice: the cytoplasmic domain is not required for normal fetal development. Blood 1999 93 10 3442 3450 2-s2.0-0033562859 (Pubitemid 29220911)
51. Suzuki K., Hayashi T., Nishioka J., Kosaka Y., Zushi M., Honda G., Yamamoto S., A domain composed of epidermal growth factor-like structures of human thrombomodulin is essential for thrombin binding and for protein C activation. Journal of Biological Chemistry 1989 264 9 4872 4876 2-s2.0-0024559613 (Pubitemid 19092897)
52. Esmon C. T., Molecular events that control the protein C anticoagulant pathway. Thrombosis and Haemostasis 1993 70 1 29 35 2-s2.0-0027161205 (Pubitemid 23225446)
53. Castellino F. J., Human protein C and activated protein C: components of the human anticoagulation system. Trends in Cardiovascular Medicine 1995 5 2 55 62 2-s2.0-0028940777 10.1016/1050-1738(94)00031-X
54. Yang L., Manithody C., Walston T. D., Cooper S. T., Rezaie A. R., Thrombomodulin enhances the reactivity of thrombin with protein C inhibitor by providing both a binding site for the serpin and allosterically modulating the activity of thrombin. Journal of Biological Chemistry 2003 278 39 37465 37470 2-s2.0-0141509969 10.1074/jbc.M307243200 (Pubitemid 37175267)
55. Preissner K. T., Delvos U., Muller-Bergbaus G., Binding of thrombin to thrombomodulin accelerates inhibition of the enzyme by antithrombin III. Evidence for a heparin-independent mechanism. Biochemistry 1987 26 9 2521 2528 2-s2.0-0023219464 (Pubitemid 17081481)
56. Maruyama I., Majerus P. W., The turnover of thrombin-thrombomodulin complex in cultured human umbilical vein endothelial cells and A549 lung cancer cells. Endocytosis and degradation of thrombin. Journal of Biological Chemistry 1985 260 29 15432 15438 2-s2.0-0022371596 (Pubitemid 16170074)
57. Moore K. L., Esmon C. T., Esmon N. L., Tumor necrosis factor leads to the internalization and degradation of thrombomodulin from the surface of bovine aortic endothelium cells in culture. Blood 1989 73 1 159 165 2-s2.0-0024589205 (Pubitemid 19040970)
58. Isermann B., Hendrickson S. B., Zogg M., Wing M., Cummiskey M., Kisanuki Y. Y., Yanagisawa M., Weiler H., Endothelium-specific loss of murine thrombomodulin disrupts the protein C anticoagulant pathway and causes juvenile-onset thrombosis. Journal of Clinical Investigation 2001 108 4 537 546 2-s2.0-0034892611 10.1172/JCI200113077 (Pubitemid 32777733)
59. White B., Schmidt M., Murphy C., Activated protein C inhibits lipopolysaccharide-induced nuclear translocation of nuclear factor kappaB (NF-kappaB) and tumour necrosis factor alpha (TNF-alpha) production in the THP-1 monocytic cell line. British Journal of Haematology 2000 110 1 130 134 (Pubitemid 30625601)
60. Joyce D. E., Grinnell B. W., Recombinant human activated protein C attenuates the inflammatory response in endothelium and monocytes by modulating nuclear factor- κ B. Critical Care Medicine 2002 30 supplement 5 S288 S293 2-s2.0-0036250817 (Pubitemid 34508005)
61. Joyce D. E., Gelbert L., Ciaccia A., DeHoff B., Grinnell B. W., Gene expression profile of antithrombotic protein C defines new mechanisms modulating inflammation and apoptosis. Journal of Biological Chemistry 2001 276 14 11199 11203 2-s2.0-0035815747 10.1074/jbc.C100017200 (Pubitemid 38089304)
62. Esmon C. T., esmonc@omrf.org Protein C anticoagulant system-anti- inflammatory effects. Seminars in Immunopathology 2012 34 1 127 132 10.1007/s00281-011-0284-6
63. Riewald M., Petrovan R. J., Donner A., Mueller B. M., Ruf W., Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science 2002 296 5574 1880 1882 2-s2.0-0037036069 10.1126/science.1071699 (Pubitemid 34596276)
64. Kerschen E. J., Fernandez J. A., Cooley B. C., Yang X. V., Sood R., Mosnier L. O., Castellino F. J., Mackman N., Griffin J. H., Weiler H., Endotoxemia and sepsis mortality reduction by non-anticoagulant-activated protein C. Journal of Experimental Medicine 2007 204 10 2439 2448 2-s2.0-34948866150 10.1084/jem.20070404 (Pubitemid 47529328)
65. Bae J. S., Rezaie A. R., Thrombin inhibits nuclear factor kappaB and RhoA pathways in cytokine-stimulated vascular endothelial cells when EPCR is occupied by protein C. Journal of Thrombosis and Haemostasis 2009 101 3 513 520
66. Bae J. S., Yang L., Manithody C., Rezaie A. R., The ligand occupancy of endothelial protein C receptor switches the protease-activated receptor 1-dependent signaling specificity of thrombin from a permeability-enhancing to a barrier-protective response in endothelial cells. Blood 2007 110 12 3909 3916 2-s2.0-37049012509 10.1182/blood-2007-06-096651 (Pubitemid 350248446)
67. Bae J. S., Rezaie A. R., Protease activated receptor 1 (PAR-1) activation by thrombin is protective in human pulmonary artery endothelial cells if endothelial protein C receptor is occupied by its natural ligand. Thrombosis and Haemostasis 2008 100 1 101 109 2-s2.0-46749084607 10.1160/TH08-02-0127 (Pubitemid 351948751)
68. Rezaie A. R., Regulation of the protein C anticoagulant and antiinflammatory pathways. Current Medicinal Chemistry 2010 17 19 2059 2069 2-s2.0-77953504483 10.2174/092986710791233706
69. Finigan J. H., Dudek S. M., Singleton P. A., Chiang E. T., Jacobson J. E., Camp S. M., Ye S. Q., Garcia J. G. N., Activated protein C mediates novel lung endothelial barrier enhancement: role of sphingosine 1-phosphate receptor transactivation. Journal of Biological Chemistry 2005 280 17 17286 17293 2-s2.0-20444443508 10.1074/jbc.M412427200 (Pubitemid 41389197)
70. Feistritzer C., Riewald M., Endothelial barrier protection by activated protein C through PAR1-dependent sphingosine 1-phosphate receptor-1 crossactivation. Blood 2005 105 8 3178 3184 2-s2.0-17044427680 10.1182/blood-2004-10-3985
71. Yang X. V., Banerjee Y., Fernández J. A., Deguchi H., Xu X., Mosnier L. O., Urbanus R. T., De Groot P. G., White-Adams T. C., McCarty O. J. T., Griffin J. H., Activated protein C ligation of ApoER2 (LRP8) causes Dab1-dependent signaling in U937 cells. Proceedings of the National Academy of Sciences of the United States of America 2009 106 1 274 279 2-s2.0-58549121206 10.1073/pnas.0807594106
72. Minhas N., Xue M., Fukudome K., Jackson C. J., Activated protein C utilizes the angiopoietin/Tie2 axis to promote endothelial barrier function. FASEB Journal 2010 24 3 873 881 2-s2.0-77952296543 10.1096/fj.09-134445
73. Elphick G. F., Sarangi P. P., Hyun Y. M., Hollenbaugh J. A., Ayala A., Biffl W. L., Chung H. L., Rezaie A. R., McGrath J. L., Topham D. J., Reichner J. S., Kim M., Recombinant human activated protein C inhibits integrin-mediated neutrophil migration. Blood 2009 113 17 4078 4085 2-s2.0-65449167251 10.1182/blood-2008-09-180968
74. Xu J., Zhang X., Pelayo R., Monestier M., Ammollo C. T., Semeraro F., Taylor F. B., Esmon N. L., Lupu F., Esmon C. T., Extracellular histones are major mediators of death in sepsis. Nature Medicine 2009 15 11 1318 1321 2-s2.0-70449107044 10.1038/nm.2053
75. Fourrier F., Chopin C., Goudemand J., Hendrycx S., Caron C., Rime A., Marey A., Lestavel P., Septic shock, multiple organ failure, and disseminated intravascular coagulation; compared patterns of antithrombin III, protein C, and protein S deficiencies. Chest 1992 101 3 816 823 2-s2.0-0026534242
76. Lorente J. A., Garcia-Frade L. J., Landin L., De Pablo R., Torrado C., Renes E., Garcia-Avello A., Time course of hemostatic abnormalities in sepsis and its relation to outcome. Chest 1993 103 5 1536 1542 2-s2.0-0027214771 (Pubitemid 23145617)
77. Bajzar L., Manuel R., Nesheim M. E., Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor. Journal of Biological Chemistry 1995 270 24 14477 14484 2-s2.0-0029044322 10.1074/jbc.270.24.14477
78. Morser J., Gabazza E. C., Myles T., Leung L. L., What has been learnt from the thrombin-activatable fibrinolysis inhibitor-deficient mouse? Journal of Thrombosis and Haemostasis 2010 8 5 868 876 2-s2.0-77953779759 10.1111/j.1538-7836.2010.03787.x
79. Mosnier L. O., Bouma B. N., Regulation of fibrinolysis by thrombin activatable fibrinolysis inhibitor, an unstable carboxypeptidase B that unites the pathways of coagulation and fibrinolysis. Arteriosclerosis, Thrombosis, and Vascular Biology 2006 26 11 2445 2453 2-s2.0-33750222459 10.1161/01.ATV. 0000244680.14653.9a (Pubitemid 44607464)
80. Markiewski M. M., Deangelis R. A., Lambris J. D., Complexity of complement activation in sepsis: crossroads in sepsis research review series. Journal of Cellular and Molecular Medicine A 2008 12 6 2245 2254 2-s2.0-57149122316 10.1111/j.1582-4934.2008.00504.x
81. Markiewski M. M., Lambris J. D., The role of complement in inflammatory diseases from behind the scenes into the spotlight. American Journal of Pathology 2007 171 3 715 727 2-s2.0-34548849117 10.2353/ajpath.2007.070166 (Pubitemid 47440971)
82. Ward P. A., Role of the complement in experimental sepsis. Journal of Leukocyte Biology 2008 83 3 467 470 2-s2.0-43349093340 10.1189/jlb.0607376 (Pubitemid 351966852)
83. Esmon C., Do-all receptor takes on coagulation, inflammation. Nature Medicine 2005 11 5 475 477 2-s2.0-18844435687 10.1038/nm0505-475 (Pubitemid 40685966)
84. Olivot J. M., Estebanell E., Lafay M., Brohard B., Aiach M., Rendu F., Thrombomodulin prolongs thrombin-induced extracellular signal-regulated kinase phosphorylation and nuclear retention in endothelial cells. Circulation Research 2001 88 7 681 687 2-s2.0-0035853404 (Pubitemid 32378137)
85. Lotze M. T., Tracey K. J., High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nature Reviews Immunology 2005 5 4 331 342 2-s2.0-17144376810 10.1038/nri1594 (Pubitemid 40516158)
86. Abeyama K., Stern D. M., Ito Y., Kawahara K. I., Yoshimoto Y., Tanaka M., Uchimura T., Ida N., Yamazaki Y., Yamada S., Yamamoto Y., Yamamoto H., Iino S., Taniguchi N., Maruyama I., The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel antiinflammatory mechanism. Journal of Clinical Investigation 2005 115 5 1267 1274 2-s2.0-20944436774 10.1172/JCI200522782 (Pubitemid 40629045)
87. Ito T., Kawahara K., Okamoto K., Yamada S., Yasuda M., Imaizumi H., Nawa Y., Meng X., Shrestha B., Hashiguchi T., Maruyama I., Proteolytic cleavage of high mobility group box 1 protein by thrombin-thrombomodulin complexes. Arteriosclerosis, Thrombosis, and Vascular Biology 2008 28 10 1825 1830 2-s2.0-53449087278 10.1161/ATVBAHA.107.150631
88. Gomi K., Zushi M., Honda G., Kawahara S., Matsuzaki O., Kanabayashi T., Yamamoto S., Maruyama I., Suzuki K., Antithrombotic effect of recombinant human thrombomodulin on thrombin-induced thromboembolism in mice. Blood 1990 75 7 1396 1399 2-s2.0-0025218438 (Pubitemid 20114874)
89. Mohri M., Oka M., Aoki Y., Gonda Y., Hirata S., Gomi K., Kiyota T., Sugihara T., Yamamoto S., Ishida T., Maruyama I., Intravenous extended infusion of recombinant human soluble thrombomodulin prevented tissue factor-induced disseminated intravascular coagulation in rats. American Journal of Hematology 1994 45 4 298 303 2-s2.0-0028230847 (Pubitemid 24109905)
90. Gonda Y., Hirata S., Saitoh K., Aoki Y., Mohri M., Gomi K., Sugihara T., Kiyota M., Yamamoto S., Ishida T., Maruyama I., Antithrombotic effect of recombinant human soluble thrombomodulin on endotoxin-induced disseminated intravascular coagulation in rats. Thrombosis Research 1993 71 4 325 335 2-s2.0-0027291336 10.1016/0049-3848(93)90201-X (Pubitemid 23222875)
91. Uchiba M., Okajima K., Murakami K., Nawa K., Okabe H., Takatsuki K., Recombinant human soluble thrombomodulin reduces endotoxin-induced pulmonary vascular injury via protein C activation in rats. Thrombosis and Haemostasis 1995 74 5 1265 1270 2-s2.0-0028853552
92. Taoka Y., Okajima K., Uchiba M., Johno M., Neuroprotection by recombinant thrombomodulin. Thrombosis and Haemostasis 2000 83 3 462 468 2-s2.0-0034064131 (Pubitemid 30148362)
93. Kaneko H., Joubara N., Yoshino M., Yamazaki K., Mitumaru A., Miki Y., Satake H., Shiba T., Protective effect of human urinary thrombomodulin on ischemia-reperfusion injury in the canine liver. European Surgical Research 2000 32 2 87 93 2-s2.0-0034018871 (Pubitemid 30251766)
94. Ozaki T., Anas C., Maruyama S., Yamamoto T., Yasuda K., Morita Y., Ito Y., Gotoh M., Yuzawa Y., Matsuo S., Intrarenal administration of recombinant human soluble thrombomodulin ameliorates ischaemic acute renal failure. Nephrology Dialysis Transplantation 2008 23 1 110 119 2-s2.0-44449114876 10.1093/ndt/gfm563 (Pubitemid 351767375)
95. Sharfuddin A. A., Sandoval R. M., Berg D. T., McDougal G. E., Campos S. B., Phillips C. L., Jones B. E., Gupta A., Grinnell B. W., Molitoris B. A., Soluble thrombomodulin protects ischemic kidneys. Journal of the American Society of Nephrology 2009 20 3 524 534 2-s2.0-62149108968 10.1681/ASN. 2008060593